Crit Rev Oncol Hematol. 2007 Nov;64(2):129-38. Epub 2007 Jun 12.

Treatment of recurrent ovarian cancer relapsing 6-12 months post platinum-based chemotherapy.

Source

European Institute of Oncology, University of Milan, Bicocca, Milan, Italy. nicoletta.colombo@ieo.it

Abstract

Platinum-containing regimens are the mainstay of initial treatment for ovarian cancer and for platinum-sensitive recurrent disease. In recurrent ovarian cancer, the effectiveness of platinum retreatment is dependent on the relapse-free and treatment-free intervals. Platinum agents can be effectively re-administered to patients with disease that relapses >12 months after completion of a platinum regimen. Ovarian cancer that relapses 6-12 months after treatment with a platinum regimen is considered partially platinum sensitive. Phase III studies of combination regimens versus platinum monotherapy and comparing various non-platinum agents administered as monotherapy generally do not report separate data for partially platinum-sensitive patients. Studies reporting data in patients with a platinum-free interval > or =6 months demonstrate advantages for pegylated liposomal doxorubicin (PLD) versus paclitaxel and PLD versus topotecan. A platinum-taxane combination or single-agent PLD is recommended for the treatment of partially platinum-sensitive disease by the UK National Institute for Health and Clinical Excellence.

PMID:: 17566758; [PubMed - indexed for MEDLINE]

Publication Types, MeSH Terms, Substances

Publication Types

Review

MeSH Terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Labome Researcher Resource - ExactAntigen/Labome

Medical

Molecular Biology Databases

PLATINUM COMPOUNDS - HSDB

Libraries

LinkOut Holdings

Supplemental Content

Save items

Related citations in PubMed

Review Changing the paradigm in the treatment of platinum-sensitive recurrent ovarian cancer: from platinum doublets to nonplatinum doublets and adding antiangiogenesis compounds. [Int J Gynecol Cancer. 2009]
Review Changing the paradigm in the treatment of platinum-sensitive recurrent ovarian cancer: from platinum doublets to nonplatinum doublets and adding antiangiogenesis compounds.
Monk BJ, Coleman RL. Int J Gynecol Cancer. 2009 Dec; 19 Suppl 2:S63-7.
Extending the platinum-free interval with a non-platinum therapy in platinum-sensitive recurrent ovarian cancer. Results from the SOCRATES Retrospective Study. [Oncology. 2006]
Extending the platinum-free interval with a non-platinum therapy in platinum-sensitive recurrent ovarian cancer. Results from the SOCRATES Retrospective Study.
Pignata S, Ferrandina G, Scarfone G, Scollo P, Odicino F, Selvaggi L, Katsaros D, Frigerio L, Mereu L, Ghezzi F, et al. Oncology. 2006; 71(5-6):320-6. Epub 2007 Sep 18.
Poor outcome of elderly patients with platinum-sensitive recurrent ovarian cancer: results from the SOCRATES retrospective study. [Crit Rev Oncol Hematol. 2009]
Poor outcome of elderly patients with platinum-sensitive recurrent ovarian cancer: results from the SOCRATES retrospective study.
Pignata S, Ferrandina G, Scarfone G, Scollo P, Odicino F, Cormio G, Katsaros D, Frigerio L, Mereu L, Ghezzi F, et al. Crit Rev Oncol Hematol. 2009 Sep; 71(3):233-41. Epub 2009 Jan 28.
Randomized trial of pegylated liposomal doxorubicin (PLD) plus carboplatin versus carboplatin in platinum-sensitive (PS) patients with recurrent epithelial ovarian or peritoneal carcinoma after failure of initial platinum-based chemotherapy (Southwest Oncology Group Protocol S0200). [Gynecol Oncol. 2008]
Randomized trial of pegylated liposomal doxorubicin (PLD) plus carboplatin versus carboplatin in platinum-sensitive (PS) patients with recurrent epithelial ovarian or peritoneal carcinoma after failure of initial platinum-based chemotherapy (Southwest Oncology Group Protocol S0200).
Alberts DS, Liu PY, Wilczynski SP, Clouser MC, Lopez AM, Michelin DP, Lanzotti VJ, Markman M, Southwest Oncology Group. Gynecol Oncol. 2008 Jan; 108(1):90-4. Epub 2007 Oct 18.
Review Randomized single-agents trials in recurrent epithelial ovarian cancer. [Int J Gynecol Cancer. 2005]
Review Randomized single-agents trials in recurrent epithelial ovarian cancer.
Sessa C, Marsoni S. Int J Gynecol Cancer. 2005 Nov-Dec; 15 Suppl 3:247-51.

See reviews... See all...

Cited by 4 PubMed Central articles

New developments in treatment of ovarian carcinoma: focus on trabectedin. [Cancer Manag Res. 2010]
New developments in treatment of ovarian carcinoma: focus on trabectedin.
Cassier PA, Duret A, Trédan O, Carrabin N, Méeus P, Treilleux I, Guastalla JP, Ray-Coquard I. Cancer Manag Res. 2010 Oct 1; 2:233-42. Epub 2010 Oct 1.
Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6-12 months) subpopulation of OVA-301 phase III randomized trial. [Ann Oncol. 2011]
Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6-12 months) subpopulation of OVA-301 phase III randomized trial.
Poveda A, Vergote I, Tjulandin S, Kong B, Roy M, Chan S, Filipczyk-Cisarz E, Hagberg H, Kaye SB, Colombo N, et al. Ann Oncol. 2011 Jan; 22(1):39-48. Epub 2010 Jul 19.
Treatment for recurrent ovarian cancer-at first relapse. [J Oncol. 2010]
Treatment for recurrent ovarian cancer-at first relapse.
Ushijima K. J Oncol. 2010; 2010:497429. Epub 2009 Dec 24.

See all...

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Substance (MeSH Keyword)
PubChem chemical substance (submitted) records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.

Recent activity

Clear Turn Off Turn On

Treatment of recurrent ovarian cancer relapsing 6-12 months post platinum-based ...
Treatment of recurrent ovarian cancer relapsing 6-12 months post platinum-based chemotherapy.
Crit Rev Oncol Hematol. 2007 Nov ;64(2):129-38. Epub 2007 Jun 12 .

PubMed
Is the "mammalian" brown fat-specific mitochondrial uncoupling protein present i...
Is the "mammalian" brown fat-specific mitochondrial uncoupling protein present in adipose tissues of birds?
Comp Biochem Physiol B. 1991 ;100(1):45-9.

PubMed
The tumor suppressor merlin interacts with microtubules and modulates Schwann ce...
The tumor suppressor merlin interacts with microtubules and modulates Schwann cell microtubule cytoskeleton.
Hum Mol Genet. 2007 Jul 15 ;16(14):1742-51. Epub 2007 Jun 12 .

PubMed
Cloning, sequencing, and mapping of an alpha-actinin gene from the nematode Caen...
Cloning, sequencing, and mapping of an alpha-actinin gene from the nematode Caenorhabditis elegans.
Cell Motil Cytoskeleton. 1991 ;20(1):69-78.

PubMed
Implementing telemonitoring in the daily routine of a GP practice in a rural set...
Implementing telemonitoring in the daily routine of a GP practice in a rural setting in northern Germany.
J Telemed Telecare. 2007 ;13(4):197-201.

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Result Filters

Display Settings:

Send to: